RG7795

RG7795
Clinical data
Other names	RG-7795; ANA773; ANA-773
Legal status
Legal status	Investigational;
Identifiers
CAS Number	892498-64-5 ;
PubChem CID	11587892;
DrugBank	DB06329;
ChemSpider	9762656;
UNII	QTI86134YL;
Chemical and physical data
Formula	C12H14N4O5S
Molar mass	326.33 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C1N(C=2C(S1)=CN=C(N)N2)[C@]3([C@H](OC(C)=O)C[C@@H](CO)O3)[H];
	InChI InChI=1S/C12H14N4O5S/c1-5(18)20-7-2-6(4-17)21-10(7)16-9-8(22-12(16)19)3-14-11(13)15-9/h3,6-7,10,17H,2,4H2,1H3,(H2,13,14,15)/t6-,7+,10+/m0/s1; Key:HOOMGTNENMZAFP-NYNCVSEMSA-N;

RG7795 (previously ANA773) is an antiviral drug candidate that as of 2015 had been in Phase II trials in hepatitis B.^[1] It is an orally-available prodrug of isatoribine,^[2] that was under development by Anadys Pharmaceuticals when it was acquired by Roche in 2011.^[3] Its active metabolite is an agonist of TLR7; activation of TLR7 causes secretion of endogenous type 1 interferons, which have antiviral activity.^[2]